H.C. Wainwright Adjusts BioXcel Therapeutics, Inc. (BTAI) Outlook Following Capital Structure Concerns
TheFly reported on April 2 that H.C. Wainwright lowered its price target on BTAI to $5 from $6 while maintaining a Buy rating.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Millennium Management Israel Englander | 1,936,760 | $2,595,258 | +6% | 0% |
| 2. | Armistice Capital Steven Boyd | 1,910,076 | $2,559,502 | 0.05% | |
| 3. | Oaktree Capital Management Howard Marks | 241,188 | $323,193 | 0% | |
| 4. | GLG Partners Noam Gottesman | 96,473 | $129,274 | +70% | 0% |
| 5. | Engineers Gate Manager Greg Eisner | 0 | $0 | 0% |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $11.00 | 2,000 | $22,000.00 | 2,000 | 2018-03-12 | Filing | |
| $9.34 | 1,554 | $14,514.36 | 168,320 | 2019-08-23 | Filing | |
| $8.83 | 6,646 | $58,684.18 | 166,766 | 2019-08-22 | Filing | |
| $8.42 | 1,800 | $15,156.00 | 160,120 | 2019-08-21 | Filing | |
| $8.89 | 974 | $8,658.86 | 9,957 | 2019-08-16 | Filing |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.09 | 6,845 | $7,426.83 | 26,175 | 2026-05-20 | Filing | |
| $1.08 | 6,560 | $7,111.04 | 26,803 | 2026-05-20 | Filing | |
| $1.09 | 6,845 | $7,426.83 | 26,300 | 2026-05-20 | Filing | |
| $1.09 | 19,419 | $21,108.45 | 69,598 | 2026-05-20 | Filing | |
| $0.35 | 165 | $58.13 | 19,957 | 2024-12-16 | Filing |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 230,168 | $308,725 | 0% | |
| 2. | 207,339 | $277,834 | 0% | |
| 3. | 131,789 | $166,054 | 0% | |
| 4. | 92,118 | $123,438 | 0% | |
| 5. | 90,300 | $121,002 | 0% |